I am interested in
  • Check All
  • Uncheck All
  • all subtypes
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
  • Diffuse Large B-Cell Lymphoma
  • Follicular Lymphoma
  • Hodgkin Lymphoma
  • Mantle Cell Lymphoma
  • Marginal Zone Lymphoma
  • Rare Lymphoma
  • T-Cell Lymphoma
  • / 1 checked
  • Only show this subtype

Interested in a specific sub-type?

Filter what you see here

  • Medical Information
  • Therapies
  • About

MZL

ASH 2016: Highlights in MZL

Anne Villeneuve | Dec 14, 2016 | Expert Opinion

Share this article

Related Medical Information

RL|CLL/SLL|TCL|DLBCL|FL|HL|MCL|MZL

EHA 2017 abstract submission deadline is just two weeks away

Feb 15, 2017
CLL/SLL|MCL|MZL

AACR 2017 poster 154/21 – Copanlisib is active as monotherapy or in combination in Mantle Cell Lymphoma, Marginal Zone…

Apr 4, 2017
DLBCL|FL|TCL|MCL|MZL

Retrospective analysis of 77 patients finds allogeneic stem cell transplantation is associated with lower overall…

Mar 17, 2017

Related Licenses

IMBRUVICA® is indicated for the treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic…

Subtype: MZL

INN: ibrutinib

Approval status: FDA

Setting: R/R

Rituxan (rituximab) is indicated for the treatment of patients with non-progressing (including stable…

Subtype: MZL

INN: rituximab

Approval status: FDA

Setting: R/R

Mozobil (plerixafor injection) is indicated in combination with granulocyte-colony stimulating factor (G-CSF)…

Subtype: MZL

INN: plerixafor

Approval status: FDA

Setting: Newly Diagnosed

Our partners

Our supporters

  • Terms and conditions
  • Cookie policy
  • Newsletter

© 2017 Lymphoma Hub

All content on this site is intended for healthcare professionals only.
If you are a patient or carer, please visit the Lymphoma Coalition.